👀👀Au 2 ème jour, les 400 yeux des participants sont cernés mais la dynamique est la même lors du GFRU à Bordeaux.
On discute vessie, rein, prostate... 👌

PSA After Radiotherapy: Key for Prostate Cancer Survival
6-month PSA level predicts long-term outcomes in patients treated with RT for localized prostate cancer.
⭕️Low PSA (<0.1 ng/mL) linked to better survival rates.
ASCO Journal of Clinical Oncology Christopher Sweeney, MBBS Matt Sydes OncoAlert…

Éternel débat...
Chirurgie ou Radiothérapie dans les cancers de la prostate à haut risque?
Réponse : essais cliniques, le consultations et décisions partagées, information claire et personnalisation !! Mario Terlizzi

New radiotracer for clear cell renal carcinoma - CA-9 targeting peptide: SUVs >100 in tumor in first 3 patients with low background activity = WOW !!

jnm.snmjournals.org/content/early/…

Debiopharm Ben Tran
JNM Peter Mac Research

Highlights #GU24 1) 38%⬆️ in OS for adjuvant pembro in RCC Toni Choueiri, MD 2) ⬆️ DFS but no OS for adjuvant pembro in UC Andrea Apolo, M.D. 3) ipi/nivo with ✅ long term data in IMDC good risk- Dr Tannir 4) olaparib and abi better together than alone on BRCA CRPC - Dr Hussian

Stellar talk by Toni Choueiri, MD ASCO #GU24 reporting the first-ever adjuvant Rx to show OS benefit in pts w/ RCC #kidneycancer in KEYNOTE-564
🌟At median f/u of 57 mo👉HR for OS 0.62
🌟HR for DFS 0.72 (consistent w/ previous analyses)
Neeraj Agarwal, MD, FASCO UroToday.com OncoAlert Kidney Cancer

Abs#3, #GU24 ASCO Subcutaneous nivolumab is non-inferior and similarly efficacious as intravenous nivolumab in mRCC #kidneycancer sabygeorge OncoAlert Uromigos Many patients will opt for subcutaneous dosing over IV dosing. Congrats to the team.

Proud of Gustave Roussy GU group celebrating 20th anniversary #GU24 🎂
Thrilled to contribute to 20years of advances in GU cancers care !

Missing Pierre Blanchard, MD Alberto Bossi Christophe Massard

Cocorico! 🇫🇷
GETUG-AFU 18 : 70 Gy vs 80 Gy in HRPC with 3 years of ADT
▶️Better PFS, PCSS and OS with 80 Gy without increasing tox = level 1 evidence SOC
Hennequin Christophe GETUG ASCO 24

📰 Le Pr Karim Fizazi est publié dans The New England Journal of Medicine (NEJM).

✨ Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer ✨

Lire la publication ➡ evidence.nejm.org/doi/full/10.10…

Melissa Barber

Congrès GFRU 21 et 22 mars 2024 à Bordeaux : les inscriptions sont ouvertes gfru.org/https-www-gfru…

Super news of the day 🤩🤩Congratulations Pierre !

It's official! 🍾

I have been appointed Editor in Chief of Radiotherapy & Oncology, aka the Green Journal, ESTRO's first official journal, starting May 2024.

Extremely honored, but also a bit frightened by the task. Big shoes to fill. Will do one step at a time...

#CFU23 radiothérapie dans le cancer du rein, oui ou non ? 🚨Nouvelle option thérapeutique🚨Caroline Pettenati Mario Terlizzi ☢️

Incredible findings at #ESMO23 : Prostate radiotherapy significantly reduces the long-term risk of obstructive uropathy in #mHSPC . This supports the use of radiotherapy in men at risk of upper urinary tract obstruction. Presented by Craig Jones > bit.ly/3SqZXPR Rashid K. Sayyid

Early salvage RT is as effective as adjuvant RT in PSA failure after RP. Final results presented by N. Clarke at #ESMO23 . ESMO - Eur. Oncology Prostate Cancer Foundation ΕΟΠΕ Neeraj Agarwal, MD, FASCO Petros Grivas Sumanta K. Pal, MD, FASCO Tian Zhang, MD, MHS Eleni Efstathiou Uromigos UroToday.com European Association of Urology (EAU) ASCO @

@FOCUS_meeting
Must read article by M Terlizzi. Trimodal therapy is a good alternative option versus surgery for selected patients, and is probably underused by urologists. Prof Ananya💙 Ploussard Guillaume Vedang Murthy Prof Param Mariappan Morgan Roupret MathieuRoumiguié Jb Beauval Roubaud Guilhem Paul Sargos

Pierre Blanchard, MD giving a superbe & convincing talk on the best way to use SBRT to delay castration

#FOCUS23 @FOCUS_meeting Thomas Zilli Prof Ananya💙 Marc-Olivier Timsit, MD, PhD 🎗️

This study demonstrate an increased use of shorter courses of radiotherapy (RT) for prostate cancer in US, and as of 2020 moderate hypofractionation makes up the majority of RT type. However, barriers to adoption continue. Daniel E Spratt ja.ma/3tlTHyc